HAVE CONFIDENCE
AT EVERY TURN

Clinical endpoint data collection, predictive analytics, and real world evidence – draw on our science, technological, global experience and credibility, learned over 15k trials, to power your clinical development with certainty, quality and speed

4.3M+

Patients Enrolled

230K

Sites Supported

600+

Drug Approvals

15K

Trials Managed

a better way to manage your clinical development

Meet goals and achieve higher quality data, reduced costs, and shortened study timelines with support from ERT.


a better way to manage your trials

Meet clinical development goals and achieve higher quality data, reduced costs, and shortened study timelines with support from ERT.

 

moving ahead requires a sure path forward

Every detail matters. We spot risks before they become problems and help you avoid costly delays through our latest solution Trial Oversight.



MINIMIZE RISK AND UNCERTAINTY

We deliver the flexibility and adaptability you need to overcome challenges for faster speed to market. Here’s how:

230k investigative sites supported
Every trial runs into unexpected challenges. With more than 15,000 trials under our belt, we’ve seen them before and have the expertise to put your trial back on course with our predictive analytics.
25 ready-to-launch analytics tools
We protect  your trial before there’s ever an issue, ensuring its success through near real-time access to study, program and enterprise-level performance.

NEWS & EVENTS

LATEST NEWS

FDA Guidance For ABPM: Capture the Data That Matters

To learn more about this FDA guidance, ABPM, and blood pressure monitoring best practices, please join us on July 18.

ERT Participates in Groundbreaking, Digital Technology Research

MOBILISE-D to revolutionize the assessment and treatment of impaired mobility for improved healthcare


Patient-Reported Outcome (PRO) Data in Oncology Trials – Part 1: Regulations

In this first of a 2-part series on the importance of PRO data in oncology drug development, we review the latest regulatory guidances recommending the use of PROs in oncology trials.